The UK life-sciences industry should not abandon America, especially in the light of the midterm elections. It should, however, stop behaving as though the only serious route to scale runs through the United States. China is becoming a principal source of pharmaceutical innovation, and British institutions now need a deliberate strategy for engaging with it on British terms.

For thirty years, the route map for a promising British biotech has been familiar: discover in Britain, finance in London, recruit in Boston, develop in America, seek FDA approval and ultimately sell into the US market.

That model has worked. It should not be abandoned.

But it is no longer enough.

China is becoming one of the principal sources of pharmaceutical innovation in the world. Its new 2026 to 2030 pharmaceutical industry plan makes the ambition explicit: rapid growth in innovative medicines, a much larger share of global first-in-class drugs, more globally significant pharmaceutical companies, stronger domestic manufacturing and deeper internationalisation.

The UK industry should take this seriously.

The question is no longer whether British life sciences should engage with China. It is how quickly, how intelligently and on what terms.

Stop Treating China Simply as a Market

Most British life-sciences companies still think about China principally as a market for their products, a manufacturing location or a potential source of capital. That view is out of date.

China increasingly needs to be treated as a source of innovation.

Global pharmaceutical companies are already licensing molecules from Chinese biotechnology companies. Chinese businesses are producing increasingly sophisticated antibody platforms, cell therapies, oncology assets, drug-delivery technologies and medical devices.

The implication for UK companies is straightforward. Every serious UK biotech and pharma company should now have a systematic process for identifying relevant Chinese science and assets.

That does not necessarily mean opening an office in Shanghai. It means ensuring that business development teams, boards and investors are actively asking what is being developed in China that could improve the pipeline, which Chinese companies could become development partners rather than competitors, and whether valuable assets should be licensed before an American competitor moves first.

This should become normal corporate practice.

Build Development Partnerships, Not Ceremonial Collaborations

Britain does not need more memoranda of understanding. It needs deals.

Universities, hospitals, investors and pharmaceutical companies should concentrate UK-China collaboration around areas where the two ecosystems have genuinely complementary capabilities.

China increasingly offers speed, scale, medicinal chemistry, translational capability, manufacturing infrastructure and a rapidly improving biotechnology ecosystem. Britain offers deep biology, world-class academic medicine, sophisticated early clinical development, the NHS, genomics, regulatory credibility and a strong international pharmaceutical industry.

Those capabilities should be deliberately connected in oncology and antibody therapeutics, cell and gene therapy, metabolic disease, neuroscience, diagnostics, medical devices, AI-enabled drug discovery and advanced manufacturing.

The objective should be commercial. A Chinese company with a promising molecule should be encouraged to conduct part of its international development in Britain. A British biotechnology company should be able to identify Chinese assets and technologies as easily as it currently searches Boston or San Francisco. British universities should create translational partnerships that can produce jointly owned companies and products rather than simply academic publications. UK investors should become far more familiar with Chinese biotechnology.

Every Board Needs Both a US Strategy and a China Strategy

Boards routinely ask management about America: the FDA strategy, the timing of a US subsidiary, American investors and the future commercial team. The same discipline should now be applied to China.

At least once a year, boards of significant UK life-sciences companies should ask whether relevant innovation is emerging from China, whether Chinese clinical or development capability could accelerate the programme, whether an asset should be licensed from China, whether a Chinese partner could improve manufacturing economics, whether China is relevant to the capital strategy, and whether the company understands the regulatory and geopolitical risks involved.

For many companies, the conclusion will quite reasonably be that China has little immediate relevance.

But that conclusion should come from analysis, not habit.

Make Britain the Internationalisation Platform for Chinese Biotech

Chinese biotechnology companies increasingly need to become international businesses. Many will require global clinical development, international regulatory experience, Western board members, global medical affairs capability, international business development and access to pharmaceutical partners outside China.

Britain should compete aggressively for that work.

A Chinese biotech seeking to internationalise should be encouraged to establish its international development organisation in Britain. It could retain discovery operations in China while building global clinical development, regulatory, medical affairs and business development capability in the UK.

Britain could provide the international management layer through which Chinese innovation reaches Europe, the United States and other markets. That would bring high-value jobs, capital and intellectual property into the UK while strengthening Britain's position at the centre of global drug development.

Government, investors and the professional-services community should actively promote Britain for precisely this purpose. If a Chinese biotech is going global, Britain should aim to be its first international base.

Turn British Executive Talent Into an Export

Many Chinese biotechnology companies possess impressive science but relatively limited experience of building truly global pharmaceutical organisations. Britain has a disproportionately large population of executives who have spent their careers doing exactly that: clinical development leaders, CMOs, regulatory executives, manufacturing leaders, business-development professionals, medical affairs leaders, experienced biotech CEOs and board directors.

Britain should deliberately connect that leadership pool with Chinese companies seeking international scale.

That does not necessarily require executives to relocate permanently to China. The growth of fractional leadership, international board roles and distributed management means British executives can increasingly help Chinese companies globalise while remaining largely based in Europe.

For the UK life-sciences professional-services sector – executive search, consulting, legal, regulatory and finance – this could become an important market in its own right.

Design Engagement Around Resilience

Greater collaboration with China cannot mean replacing dependence on America with dependence on China. The objective should be optionality.

Companies should avoid structures in which a single Chinese supplier controls an irreplaceable component of development or manufacturing. Critical processes should be capable of transfer. Essential intellectual property should remain accessible outside China. Sensitive biological and patient data should be carefully governed. Companies should understand whether particular partnerships could restrict future access to US federal funding, customers or investors. Supply chains should be deliberately redundant.

The right principle is simple: collaborate deeply, but never become trapped.

That principle should apply equally to American and Chinese partners.

Distinguish Technology Risk From Nationality

The debate about China frequently becomes too crude. China is treated either as an enormous commercial opportunity to be embraced without qualification or as a strategic threat from which Western science should progressively decouple. Neither position is particularly useful to industry.

The appropriate questions are what technology and data are involved, who controls the intellectual property, whether there are significant dual-use applications, where manufacturing is located, what happens if the political environment deteriorates, whether the relationship can be unwound, and whether it could compromise access to another important market.

That is how sophisticated multinational companies already think about geopolitical exposure. British biotechnology needs to do the same.

Sensitive genomic databases, certain synthetic-biology technologies and capabilities with credible dual-use potential plainly require stronger safeguards. Applying identical restrictions to a conventional oncology antibody or routine medicinal-chemistry collaboration makes little strategic sense.

Britain should become better at distinguishing risk that needs managing from risk that merely needs understanding.

UK Investors Need to Understand China Better

Most British specialist life-sciences investors understand the US ecosystem intimately. Far fewer have comparable familiarity with Chinese biotechnology. That creates a blind spot.

Investors should build systematic coverage of Chinese drug discovery and medtech companies, not necessarily because they intend to invest directly in China, but because Chinese innovation increasingly affects the competitive position and valuation of Western companies.

When assessing a European oncology biotech, investors should know whether three Chinese companies are developing similar molecules. When evaluating a platform technology, they should know what competing Chinese platforms exist. When considering licensing assumptions, they should understand whether a Chinese biotech might become the most logical partner.

Chinese competitive intelligence should become part of mainstream UK life-sciences investment analysis.

Compete for Chinese Research and Development Investment

The UK Government spends enormous effort attracting American pharmaceutical investment. It should compete just as energetically for Chinese research and development.

The prize should not primarily be Chinese ownership of existing British companies. It should be new investment.

Chinese pharmaceutical groups should be encouraged to establish European R&D headquarters, clinical development centres, international regulatory teams, translational research collaborations, manufacturing facilities and global business-development operations in Britain.

That creates additional economic activity rather than simply transferring ownership of existing assets.

Copy Some of China's Industrial Discipline

The UK Life Sciences Sector Plan is significantly better than previous strategies because it recognises that science alone is insufficient. It addresses capital, regulation, trials, manufacturing, NHS adoption and investment.

But Britain remains much more comfortable measuring inputs than outputs. We measure R&D expenditure, venture investment, foreign direct investment, clinical-trial performance and manufacturing investment. All of these matter. Ultimately, however, the industry exists to produce medicines, devices and companies.

China has set itself tangible objectives around first-in-class medicines, innovative devices, global products and large pharmaceutical companies. Britain should adopt some of that discipline.

Alongside R&D and investment targets, the UK should track the number of globally significant medicines created by UK companies; UK-originated first-in-class assets reaching late-stage development; £1 billion, £5 billion and £10 billion UK life-sciences companies; the proportion of British innovations manufactured in Britain; and UK companies scaling internationally without being sold prematurely.

Those are harder measures. They are also closer to what actually matters.

Do Not Pivot From America. Add China.

So should Britain switch its life-sciences bet from America to China? No.

The United States remains indispensable to British life sciences. Its pharmaceutical market, capital markets, scientific institutions, FDA, biotech clusters and management talent cannot sensibly be replaced.

But neither should Britain behave as though China is simply a secondary market.

The world is moving towards three major life-sciences ecosystems: the United States, China and a more fragmented European system in which Britain is attempting to establish a distinctive position.

Britain's opportunity is to be the most connected of the three.

We should be able to discover a medicine in Cambridge, finance it in London, partner part of the science in Shanghai, conduct trials through the NHS, raise additional capital in Boston and manufacture it in Britain.

The strategic mistake would be forcing British companies to choose prematurely between America and China. The competitive advantage is having credible access to both.

What the Industry Should Do Now

1. First: Every substantial UK biotech and pharma board should formally review its China strategy – not simply its Chinese sales strategy, but its innovation, licensing, development, manufacturing and capital strategy.

2. Second: British business-development teams should systematically scout Chinese pipelines. China should become part of routine global asset-search activity.

3. Third: British universities and translational institutions should prioritise commercial UK-China partnerships over ceremonial academic relationships. Measure companies, licences, trials and products – not memoranda.

4. Fourth: UK investors should build genuine China expertise. Understanding Chinese biotechnology is becoming necessary to value Western biotechnology correctly.

5. Fifth: Government should make Britain the preferred international headquarters for Chinese biotech companies going global. That means targeted investment promotion, regulatory support and access to the UK clinical-development ecosystem.

6. Sixth: British life sciences should recruit people who understand both systems. Executives, board members, investors and advisers capable of working comfortably across Britain, America and China will become disproportionately valuable.

The industry has spent thirty years building the bridge between Britain and America. We should keep it.

But China is building another centre of gravity in global life sciences, and Britain should not wait until that transformation is complete before constructing the second bridge.

The winners in the next decade will not necessarily be the countries that choose the right superpower. They will be the ecosystems capable of working intelligently with both.

Selected Sources

1. UK Life Sciences Sector Plan

2. China Pharmaceutical Industry Fifteenth Five Year Plan – Policy Interpretation

3. UK National Security and Investment Act Guidance